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ABSTRACT

The present invention provides, inter alia, a PC12 cell
quiescently infected With a neurotropic virus. Preferred
quiescently-infected neural cells are those Wherein the neu

Su et al., Human Corneal Cells and Other Fibroblasts Can

rotropic virus is a neurotropic herpes virus. Methods related

Stimulate the Appearance of Herpes Simplex Virus from
Quiescently Infected PC12 Cells. Journal of Virology

to these and other materials are also provided.

73(5):4171—4180, 1999*
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NEURONAL CELL MODEL AND METHODS
OF USE THEREFOR

lack of virus production folloWing removal of the inhibitory

agent, (Wilcox and Johnson, 1988) (iii) the presence of

latency-associated transcripts (LATs) (Doerig et al, 1991;
Smith et al, 1994), (iv) impaired reactivation of thymidine
kinase negative virus (Wilcox et al, 1992), and (v) inducible
reactivation (Halford et al, 1996; Moriya et al, 1994; Smith

This application claims priority to US. Provisional
Patent Application No. 60/078,850, ?led Mar. 20, 1998.
This Work Was supported by NIH grant number NIH
(NIDR) R29 DE11104; the government may have certain
rights in this invention.
FIELD OF THE INVENTION

et al, 1992; Wilcox and Johnson, 1988; Wilcox and Johnson

1987; Wilcox et al, 1990). Nevertheless, preparation of
dissected ganglia is inconvenient, material is limited, animal
10

In this disclosure, it is demonstrated that neurally
differentiated cells can be infected With viruses in a manner

that supports a long-term non-productive infection. This
model When compared to others is unique in that 1) quies
cent infection is established in a neuronal cell line that has

for studying the molecular details of the establishment,
maintenance and reactivation stages of latency. Cell culture
15

features reminiscent of ganglionic neurons, 2) an inhibitor of

DNA synthesis is needed only to establish the quiescent
state, not maintain it, 3) an inhibitor of viral gene expression
is not required to establish the quiescent state, 4) the
non-productive state is reversible With spontaneous and
inducible reactivation, and 5) quiescence is long term.
In particular, neuronally differentiated PC12 cells, estab
lished from pheochromocytoma of rat adrenal medulla, are
used to host a persistent viral infection. First, cells are

differentiated by groWing cells in de?ned medium contain
ing nerve groWth factor. Under these conditions cells extend
neurites, develop electrical excitability and express genes

20

These models, hoWever required loW input multiplicities
25

30

35

quiescent and persistent infection comes from assays dem
onstrating that cells survive the infection, a nonproductive
viral state is established in the majority of cultures, and cells
40

BACKGROUND OF THE INVENTION

been demonstrated (Block et al, 1994). Block also differs

50

from the present invention in that Block asserted that
WithdraWal of NGF from a serum-containing medium
resulted in reactivation, implying that NGF and serum Were
necessary in any such model.
Previous studies have demonstrated NGF-differentiated
PC12 (Nd-PC12) cells can be maintained as non-dividing
cultures both in the presence and absence of serum (Greene,

55

1978; Greene and Tischler, 1976). These cultures have been
studied on non-coated (Block et al, 1994) and collagen
coated dishes (Greene and Tischler, 1976). Other studies

of neurons latently infected in animal models (Bloom et al,
1996; Hill et al, 1996; Maggioncalda et al, 1996; Mehta et

al, 1995; Ramakrishnan 1994; SaWtell, 1997; SaWtell et al,
quantitation of reactivation events When measuring virus
production at the recurrent site as a result of in?uences of

indicate that a signi?cant portion of PC12 cells cultured in
the presence of serum continue to divide (Goodman et al,

transport, replication in epithelium, and the immune
response.

1979; Ignatius et al, 1985).
60

the eventual appearance of virus in the host. Tissue culture

models derived from neuronal and sympathetic ganglia have
properties of the in vivo system including:
restricted
transcription of the HSV genome (Doerig et al, 1991;
Halford et al, 1996; Smith et al, 1992; Smith et al, 1994), (ii)

regulation and expression (Frazier et al, 1996a; Frazier et al,
1996b; Jordan et al, 1998; Leib et al, 1991; Xie et al, 1996)

45 these cells to harbor HSV-1 in a “latent-like” state has not

different primary groWth phenotypes, (ii) the limited number

A major advantage of tissue and cell culture models
includes the ability to observe virus at the single cell level
Without the overlay of immunological events that modulate

The rat pheochromocytoma (PC12) cell line (used in the
present model) is of neural crest origin and can be morpho
logically differentiated With the addition of nerve groWth
factor (Greene and Tischler, 1976). These cells have been
shoWn to be permissive to HSV-1 infection (Bloom and
Stevens, 1994; Rodahl and Haar, 1997; Rubenstein and
Price, 1983a; Rubenstein and Price 1983b, Rubenstein and
Price, 1984), and have been used to examine HSV-1 gene

(HardWicke and Schaffer, 1997). The relevance of these
studies, hoWever remains incomplete since the ability of

supports viral latency, in particular, HSV-1 latency, has

1998; Thompson and SaWtell, 1997), and (iii) inaccurate

to prevent virus production. A cell line that has neural
morphology and physiology, can survive infection and per
mit viral production, alloW establishment of a long term
nonproductive viral infection, and support virus in a state

and the function of HSV origins of DNA replication

The lack of a universally accepted neural cell-line that
restricted the understanding of the molecular events
involved in reactivation from latency. As a result, animals
and tissue culture have served to provide an understanding
of the mechanisms of this event. Animal models, hoWever,
are limited by dif?culties. These include:
latency and
reactivation events that are in?uenced by viral strains With

and/or the use of replication inhibitors such as anti-viral
agents, inhibitory temperatures, or the use of a mutant virus,

suitable for reactivation studies Would be more desirable.

of the antiviral treatment. Evidence of establishment of a

support spontaneous and inducible virus production.

Wigdahl et al, 1982a; Wigdahl et al, 1982b; Wigdahl et al,
1983) and lymphocytes (Hammer et al, 1981; Youssou?an et
al, 1982) have enabled the study of HSV-1 during a latent

de?ned regimen of media changes are used to establish a

quiescent and nonproductive state folloWing the WithdraWal

also alloWs for an unlimited supply of a de?ned host cell and

the ability to manipulate genetic material. Over the past 25
years, cell culture systems using ?broblast cultures (Harris
and Preston, 1991; Jamieson et al, 1995; O’Neill, 1977;
O’Neill et al, 1972; Russell et al, 1987; Scheck et al, 1989;

like state.

encoding neuronal cell-speci?c proteins (Green and Tischler
1976; Green and Tischler 1982). Cells are maintained in
serum-free medium to render them nondividing. Next, cells
are inoculated With neurotropic virus (eg., human herpes
virus) under conditions that restrict viral propagation. A

use is required, and axotomy introduces traumatic factors
that in?uence reactivation of virus.
For the above reasons, cell culture models are important

65
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neurotropic virus is a neurotropic herpes virus. More pre
ferred are those methods Wherein the neurotropic herpes
virus is a human herpes simplex 1 virus. HoWever, those
methods Wherein the neurotropic virus is selected from the
group consisting essentially of varicella zoster viruses,

polyoma viruses, measles viruses, human immunode?ciency

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,
epstein barr viruses, hepatitis viruses, coronaviruses, cox

sackie viruses, rabies viruses, flaviviruses, paramyxoviruses,
togaviruses, and rhinoviruses are also preferred. Methods
Wherein the neurotropic herpes virus is a human herpes
simplex 1 virus and the antiviral agent is acyclovir are
preferred, especially methods Wherein said container is
incubated With an antiviral composition for approximately 5
to 12 days, more especially methods Wherein said container
is incubated at a temperature less than 40 degrees Celsius,
and most especially Wherein said serum free medium alloWs
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for constant cell density and imparts neural characteristics to
said cells.
Also provided are methods of reactivating a quiescent
virus from neural cell, comprising: introducing a reactivator
to a quiescendy-infected neural cell described herein.
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simplex 1 virus. HoWever, those quiescently-infected neural
cells Wherein the neurotropic virus is selected from the

determining if reactivation has been suppressed.
Also provided are methods for determining the ability of
55 a test reagent to induce virus reactivation from in a neural

cell, comprising introducing a test reagent to a quiescently
infected neural cell described herein; and determining if
reactivation has been induced.
Also provided are methods for eliciting phenotypic

79:2207—2210.
Citation of the above documents is not intended as an

change in a neural cell, introducing a reactivator to a

admission that any of the foregoing is pertinent prior art. All

iting a phenotypic change in said neural cell. Preferred are

statements as to the date or representation as to the contents

such methods Wherein said phenotypic change is selected

of these documents is based on subjective characterization
of information available to the applicant, and does not
constitute any admission as to the accuracy of the dates or
contents of these documents.

quiescently-infected neural cell described herein, and elic

65

from the group consisting of synthesis of myelin, synthesis
of neurotransmitter, cell death, and viral shedding.
Also provided are methods for determining the suscepti
bility of a person infected With a quiescent virus to reacti

US 6,268,124 B1
6

5
vation by a reagent, comprising introducing a reactivator to
a quiescently-infected neural cell described herein, Wherein

detectable gene products, no detectable viral gene

the neurotropic virus is a strain isolated from a person

“reactivator” means a reagent Which Will cause reactivation

infected With said neurotropic virus; and determining the
relative magnitude of phenotypic or genomic reactivation.

“reactivation” means any change in phenotype or genotype

transcription, except for latency associated transcripts.
of quiescent virus.

Also provided are methods to determine the ability of a

from a quiescent state.

non-neurotropic virus to become quiescent and/or reactivat

“reagent” means a composition or an environmental

able in a neural cell line, comprising introducing a non
neurotropic virus to differentiated and viable PC12 cells in
a serum-free medium, said differentiated PC12 cells being in
a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

“virus” means the de?nition as understood by those in the
art, as Well as viroid particles such as prions, and includ

condition, temperature, ultraviolet radiation, etc.
10

ing natural and arti?cial alterations thereof (eg. mutations

(eg. temperature sensitive mutations), including deletions,

viral activity; and removing said antiviral agent from said

insertions, etc.)

container; and determining said non-neurotropic virus’s
ability to become quiescent and or reactivatable.
Also provided are methods to identify nucleic acid mol
ecules and/or proteins involved in virus reactivation, com

15

FIG. 1 shoWs the groWth characteristics of long-term
cultures of NGF differentiated PC12 cells.

prising reactivating a quiescently-infected neural cell
described herein With a reactivator; and identifying nucleic

FIG. 2 shoWs induced HSV-l production from quiescent

acid molecules and/or proteins Which are uniquely expressed

infected PC12 cell cultures.
FIG. 3 shoWs induction of HSV-1 from long term

during reactivation.
Also provided are methods to identify the origins of DNA

quiescently-infected PC12 cells.
FIG. 4 shoWs Southern analysis of HSV-1 transcripts
produced during the establishment and maintenance of the

replication important to virus reactivation, comprising reac
tivating a quiescently-infected neural cell described herein
With a reactivator; and identifying the origins of replication

25

Which are uniquely associated With reactivation.
Also provided are methods to determine a reagent’s
ability to inhibit establishment of a quiescent viral infection,

quiescent phase of infection.
DETAILED DESCRIPTION OF THE
INVENTION

comprising introducing a non-neurotropic virus to differen

The present invention provides, inter alia, neural cells

tiated and viable PC12 cells in a serum-free, test reagent

comprising a PC12 cell quiescently infected With a neuro

containing medium, said differentiated PC12 cells being in
a container; and incubating said container With an antiviral

reagent for a time necessary to accomplish quiescence of
viral activity in the absence of said test reagent; and remov

ing said antiviral agent from said container; and determining
said test reagent’s ability to inhibit quiescence.

BRIEF DESCRIPTION OF THE FIGURES

35

Also provided are methods to screen an attenuated virus’

tropic virus. Preferred quiescently-infected neural cells are
those Wherein the neurotropic virus is a neurotropic herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic virus is a neurotropic human herpes
virus. More preferred are quiescently-infected neural cells
Wherein the neurotropic herpes virus is a human herpes

simplex 1 virus. HoWever, those quiescently-infected neural

relative ability to be reactivated, comprising introducing a

cells Wherein the neurotropic virus is selected from the

reactivator to a quiescently-infected neural cell described

group consisting essentially of varicella Zoster viruses,

herein, Wherein the neurotropic virus is an attenuated virus;
and determining the relative magnitude of reactivation.
For the purposes of the present application, the folloWing
terms shall have the folloWing meanings:

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,

“a” or “an”, When describing a noun, refers to one or more
of that noun.
45

togaviruses, and rhinoviruses, are also preferred.

“antiviral reagent” means a reagent Which prevents viral
groWth or DNA replication in a cell.
“composition” means any compound or composition made
by any means. “Composition” includes synthetic or

described in the examples. PC12 cell variants are Within the
scope of the present invention, as are any cells derived from
the neural crest. These materials can be commercially

polyoma viruses, measles viruses, human immunode?ciency
epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,
Certain PC12 cells are available commercially as

naturally-occurring compounds or compositions, Whether

obtained from American Type Culture Collection (ATCC,

puri?ed or not, and can include: biologicals, chemicals,

Rockville, Md.) or other commercial entities. These cells are
Within the scope of the present invention as Well.

herbal extract(s); precursor(s); metabolite(s); and
ingredient(s), including enantiomer(s) of a racemic mix
ture. The de?nition of “composition” includes compounds
produced in situ by virtue of an immune response (ie.

Within the meaning of each of the viruses listed in the
claims are several hundreds of “strains” of those viruses. For
55

instance, human herpes virus 1, human herpes virus 6,
human herpes virus 7, and human herpes viruses 8 are
“strains” of human herpes virus. The strains of each virus
type is, of course, included Within the scope of the present

immunoglobulins and compounds involved in
in?ammation), as Well as organisms, such as: viruses,

bacteria and fungi.

invention. For instance, human herpes simplex virus 1

“isolated” means physically removed from a form found in
nature. For instance, Whole cells, a crude cell extract,

includes the strains listed in the examples, as Well as these

puri?ed virus, molecularly engineered virus, or arti?cial

other strains, such as 17+, KOS, McKrae, Macroplaque,
Patton, and F.

virus Would be “isolated” virus.
“neurotropic virus” means any virus Which is capable of

Viruses can be obtained by purchasing them commer
cially (as part of a cell line or tissue sample) from ATCC or

infecting neurons, including viruses Which only tran
siently infect neurons.
“quiescent” or “quiescence” means the absence of detectable
infectious particles in the media and Within the cells, no

65

by obtaining them according to the procedures Well knoWn
in the art, such as by obtaining clinical isolates, or cultures
from researches in the ?eld. Textbooks Which discuss

US 6,268,124 B1
7

8

manipulations of viruses are many, including: Fields &

mented reagent or virus in order to transiently inhibits viral
groWth. It is optimal to change the media as described in the
examples, but it is not necessary, so long as the cells are

Knipe, Fundamental Virology; Luria et al, General Virology;
and Fenner et al., Molecular Virology. The present
quiescently-infected neural cells can be made by the meth
ods disclosed herein.
Particularly useful in the preparation of the neural cells
are the examples, although variations as described herein

acceptably viable.
Also provided are methods of reactivating a quiescent
virus from neural cell, comprising: introducing a reactivator
to a quiescently-infected neural cell described herein.

Will also produce the present materials. Moreover, certain
reasonable optimiZation of the methods can be accomplished

This aspect of the invention is particularly useful in
studying reactivation, as Well as in studying quiescence. The
information gleaned from reactivation and quiescence stud
ies Will be of bene?t in drug discovery. The preferred

according to methods Well-known in the art.

Also provided are methods of establishing quiescently
infected neural cells, comprising introducing a neurotropic

quiescently-infected neural cells for use in this embodiment

virus to neurally-differentiated and viable PC12 cells in a

are those comprising neurotropic herpes viruses, preferably

serum-free medium, said differentiated PC12 cells being in
a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

HSV-1. The neural cells can be prepared as described herein
15

viral activity; and removing said antiviral agent from said

Also provided are methods for determining the ability of

container. Preferred such methods are those Wherein the

a test reagent to suppress virus reactivation from a

neurotropic virus is a neurotropic herpes virus. More pre
ferred are those methods Wherein the neurotropic herpes
virus is a human herpes simplex 1 virus. HoWever, those
methods Wherein the neurotropic virus is selected from the
group consisting essentially of varicella Zoster viruses,

quiescently-infected neural cell, comprising introducing a
test reagent to a quiescently-infected neural cell described

herein; and introducing to said neural cell a reactivator; and

determining if reactivation has been suppressed.
This aspect of the invention is particularly useful for

polyoma viruses, measles viruses, human immunode?ciency

viruses, papillomaviruses, adenoviruses, cytomegaloviruses,

25

epstein barr viruses, hepatitis viruses, coronaviruses, cox
sackie viruses, rabies viruses, ?aviviruses, paramyxoviruses,

are those comprising neurotropic herpes viruses, preferably

be accomplished by any means, including, for example,
those means described in the examples, or other Well-known
means.

Also provided are methods for determining the ability of
35

infected neural cell described herein; and determining if
reactivation has been induced.

This aspect of the invention is particularly useful for
identifying potential reactivators. In one aspect, this embodi
ment is useful in drug discovery as part of a toxicology
screen. For example, if a reagent such as a drug (or potential
drug), vaccine, carrier, food, or environmental condition is

plating technique; collagen need not be used, but ef?ciency
Will be improved if it is. Moreover, the plates need not be as
con?ning as described in the examples; other surfaces,
including different shapes and siZes, can be used, so long as

implicated through the use of this method as a reactivator of
45

greater than 15, although it the examples describe preferred
multiplicities for HSV-1 When high reactivation rates are
desired. HoWever, in certain instances, it may be optimal to
have loW reactivation rates, depending on the particular use
of the neural cells. In that case, loWer multiplicities Would be
optimal. The antiviral reagent used can be any Which causes

quiescent virus, it Would be advisable for an infected indi
vidual to avoid the reagent, since reactivation of virus is
normally a detrimental to the individual. The preferred
quiescently-infected neural cells for use in this embodiment

are those comprising neurotropic herpes viruses, preferably
HSV-1. The neural cells can be prepared as described herein,

introducing a test compound can be accomplished by any
means Which causes interaction betWeen the test compound

and the neural cells, and determining reactivation can be

quiescence of the neurotrophic virus. The exempli?ed
reagent, acyclovir, may be optimiZed chemically for this
purpose, or other antivirals may be used. For example, AZT,

a test reagent to induce virus reactivation from a neural cell,

comprising introducing a test reagent to a quiescently

for constant cell density and imparts neural characteristics to
said cells.
The methods described herein may utiliZe the speci?c
conditions described in the examples, but may also vary
therefrom. Variations include the use of collagen in the

a viable cell culture can be maintained for the length of time
desired. The multiplicity of infection may be from 0.5 to

identifying potential anti-viral drugs. The preferred
quiescently-infected neural cells for use in this embodiment
HSV-1. The neural cells can be prepared as described herein,
introducing a reactivator can be accomplished by any means
Which causes reactivation, and determining reactivation can

togaviruses, and rhinoviruses are also preferred. Methods
Wherein the neurotropic herpes virus is a human herpes
simplex 1 virus and the antiviral agent is acyclovir are
preferred, especially methods Wherein said container is
incubated With an antiviral composition for approximately 5
to 12 days, more especially methods Wherein said container
is incubated at a temperature less than 40 degrees Celsius,
and most especially Wherein said serum free medium alloWs

and introducing a reactivator can be accomplished according
by any means Which causes reactivation.

accomplished by any means, including, for example, those
55

means described in the examples, or other Well-known

lamidudine (3TC) indovir (IDV), gancyclovir, fancyclovir,
foscamite, idoxyuridine, phosphoacetic acid, 5-?uorouracil,

means.

or similar compounds and analogs thereof may be used. The
concentrations of the compound used to cause quiescence

change in a neural cell, introducing a reactivator to a

can also be modi?ed as necessary. Moreover, a combination

iting a phenotypic change in said neural cell. Preferred are

(eg. tWo or more) of antiviral drugs may be used. Incubation
of the PC12 cells With the antiviral is optimally that
described in the examples, but can be more or less, depend

such methods Wherein said phenotypic change is selected

Also provided are methods for eliciting phenotypic
quiescently-infected neural cell described herein, and elic

from the group consisting of synthesis of myelin, synthesis
of neurotransmitter, degradation of neurotransmitters, cell
death, and viral shedding.

ing on the particular reagent used. OptimiZation of the
incubation schedule is Within the skill of the art. Lastly, the
media used can be any that alloWs viable cell groWth, so long
as it alloWs for constant cell density and may be supple
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This aspect of the invention is particularly useful in
studying disease states, such as multiple sclerosis, or other
neuron-associated diseases. The neural cells can be directed
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via molecular techniques, for example, to result in disease

Also provided are methods to determine a reagent’s

state upon activation. Alternatively, the neural cells can be
directed to be positive in?uences on the environment, such

ability to inhibit establishment of a viral infection, compris
ing introducing a non-neurotropic virus to differentiated and

that gene therapy studies Will be possible using this embodi

viable PC12 cells in a serum-free, test reagent-containing
medium, said differentiated PC12 cells being in a container;
and incubating said container With an antiviral reagent for a

ment. In all aspects of the present embodiment, the methods
Will be useful for drug discovery in that the mechanisms of
phenotypic change can be studied. The preferred
quiescently-infected neural cells for use in this embodiment

time necessary to accomplish quiescence of viral activity in
the absence of said test reagent; and removing said antiviral
agent from said container; and determining said test

are those comprising neurotropic herpes viruses, preferably
HSV-1.

reagent’s ability to inhibit quiescence.

Also provided are methods for determining the suscepti

This aspect of the invention is particularly useful for

bility of a person infected With a quiescent virus to reacti

identifying reagents Which could be used as an anti-viral

vation by a reagent, comprising introducing a reactivator to
a quiescently-infected neural cell described herein, Wherein
the neurotropic virus is a strain isolated from a person

infected With said neurotropic virus; and determining the
relative magnitude of phenotypic or genomic reactivation.
This aspect of the present invention is particularly useful

15

drug. The reagents identi?ed as inhibiting the establishment
of quiescence Would be particularly effective to administer
during the ?rst lytic phase of a viral infection. The preferred
neural cells for use in this embodiment are those Which are

neurotropic herpes viruses, speci?cally HSV-1.

for patient diagnosis and directed medical care. Since some
strains are more reactivatable than others, it is important to

Also provided are methods to screen an attenuated virus’

relative ability to be reactivated, comprising introducing a

determine the aggressiveness and/or timing of treatment.
The present embodiment, for example, can identify those
individuals Who harbor a strain particularly reactivatable by

reactivator to a quiescently-infected neural cell described

herein, Wherein the neurotropic virus is an attenuated virus;
and determining the relative magnitude of reactivation.
This aspect of the invention is particularly useful to
determine the reactivatability of potential or actual vaccines.

sunlight, in Which those patients could use sunscreen or
avoid the sun. The method Would provide information to
patients Who have a less reactivatable strain, so that sup 25 Vaccines Which can reactivate, Whether alone, or in combi

pressor drug levels can be loWered in comparison to those
Who have a highly reactivatable strain. The preferred
quiescently-infected neural cells for use in this embodiment

are those comprising neurotropic herpes viruses, preferably

nation With an additional reagent, Would be potentially
dangerous. In other Words, this aspect of the invention can
be used a specially-designed toxicology assay. The preferred
quiescently-infected neural cells for use in this embodiment

HSV-1.
Also provided are methods to determine the ability of a

HSV-1.

are those comprising neurotropic herpes viruses, preferably

non-neurotropic virus to become quiescent and/or reactivat
EXAMPLES

able in a neural cell line, comprising introducing a non
neurotropic virus to differentiated and viable PC12 cells in
a serum-free medium, said differentiated PC12 cells being in
a container; and incubating said container With an antiviral
reagent for a time necessary to accomplish quiescence of

Example 1
Media, Cell Lines and Virus

Rat pheochromocytoma (PC12) and Vero (African green
monkey kidney) cells Were obtained from ATCC (Rockville,
Md.). All culture media and supplements Were purchased
from Gibco BRL (Gaithersburg, Md.) unless otherWise

viral activity; and removing said antiviral agent from said

container; and determining said non-neurotropic virus’s
ability to become quiescent and or reactivatable.

indicated. PC12 cells Were groWn in RPMI 1640 media

This aspect of the present invention is particularly useful

containing 5% fetal bovine serum (FBS) and 10% heat

to identify additional viruses Which may be amenable to the

inactivated horse serum

present invention. The preferred quiescently-infected neural

Vero cells Were groWn and

cells for use in this embodiment are those comprising 45 maintained in M199 medium containing 5% FBS. Cells
Were incubated at 37° C. in a humidi?ed incubator With 5%

neurotropic herpes viruses, preferably HSV-1.

CO2. All media Was supplemented With penicillin (100

Also provided are methods to identify nucleic acid mol
ecules and/or proteins involved in virus reactivation, com

units/ml) and streptomycin (100 mg/ml). HSV-1 KOS (M)
Was a kind gift of R. Thompson (University of Cincinnati,
Cincinnati, Ohio). HSV-1 strain 17 Was a kind gift of N.

prising reactivating a quiescently-infected neural cell
described herein With a reactivator; and identifying nucleic

Fraser (Wistar Institute, Philadelphia, Pa.). Viral stocks Were

acid molecules and/or proteins Which are uniquely expressed

prepared in Vero cells and maintained at —85° C. Virus
production Was determined using supernatants from infected
cultures in a direct plaque assay (DPA) on monolayers of

during reactivation.
This aspect of the present invention is particularly useful
for general scienti?c research or to study possible targets for

drug discovery. The preferred quiescently-infected neural

Vero cells as previously described (Miller and Smith, 1991).
55

cells for use in this embodiment are those comprising

Example 2
Morphologic Differentiation

neurotropic herpes viruses, preferably HSV-1.
Also provided are methods to identify the origins of DNA

replication important to virus reactivation, comprising reac

PC12 cells Were collected from ?asks, dissociated by
passage through a 22-gauge needle and plated on 6-or

tivating a quiescently-infected neural cell described herein
With a reactivator; and identifying the origins of replication

12-Well tissue culture dishes (Becton Dickinson LabWare,
Franklin Lakes, N.J.) coated With rat tail collagen type 1

Which are uniquely associated With reactivation.

(Becton Dickinson), unless otherWise indicated. Collagen

This aspect of the present invention is particularly useful
for general scienti?c research or to study possible targets for

Was applied as recommended by the supplier. Morphologic

drug discovery. The preferred quiescently-infected neural
cells for use in this embodiment are those comprising

neurotropic herpes viruses, preferably HSV-1.

differentiation Was initiated With 50 ng/ml of 2.5 S mouse
65

nerve groWth factor (NGF) (Becton Dickinson) in
RPMI1640 media containing 5% FBS and 10% HS or RPMI
containing 0.1% bovine serum albumin, fraction V (BSA) as

US 6,268,124 B1
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described by Green and Tischler (1976), Green (1978) and

NT nylon membranes (Micron Separation Inc., Westboro,

Gunning et al (1981). Morphologic differentiation Was con

Mass.) by capillary action folloWing denaturation and neu

?rmed by microscopic visualization of dendritic processes.
Media Was changed every 2—3 days.

traliZation. Membranes Were hybridiZed to digoxigenin

Example 3

probes speci?cfor HSV-1 gene sequences. The blots Were

labeled (DIG Oligonucleotides 3‘ end labeling and DIG
Luminescent Detection Kits [Boehringer Mannheim])

Establishment of a Quiescent and Persistent Infection

scanned using the Phosphorimager (Molecular Dynamics,

Neurally-differentiated PC12 cells (Nd-PC12) Were
infected With virus, in a volume of 0.4 or 1.0 ml/Well, for 12

and 6-Well plates, respectively, Without agitation at the
indicated multiplicity of infection (MOI) overnight at 37° C.

10

sage Were determined for each sample to monitor the reverse

Acycloguanosine (ACV), purchased from Sigma (St. Louis,

transcriptase reaction.

Mo.) Was added to the medium, at the indicated

concentrations, from days —1 to the indicated time post
infection (p.i.). After ACV WithdraWal, a quiescent state
(i.e., free of detectable infectious virus in culture superna
tants and lysates) Was maintained for at least 7 days prior to

15

induction.

Example 4
Reactivation Stimuli

Sunnyvale, Calif.) and analyZed With GPTools softWare
(Biophotonics, Ann Arbor, Mich.). Levels of the host
glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mes

20

Example 7
Conditions for Maintenance of Long Term, Non-dividing
Differentiated PC12 Cultures
Previous studies have demonstrated NGF-differentiated
PC12 (Nd-PC12) cells can be maintained as non-dividing
cultures both in the presence and absence of serum (Greene,

1978; Greene and Tischler, 1976).These cultures have been
studied on non-coated (Block et al, 1994) and collagen

HSV-1 quiescently infected PC12 cells (QIF-PC12),that

coated dishes (Greene and Tischler, 1976). Preliminary

Were free of detectable infectious virus, Were subjected to

studies in our laboratory, hoWever, indicated that a signi?
cant portion of PC12 cells cultured in the presence of serum
continued to divide and is consistent With the ?ndings of

RPMI media containing BSA and NGF supplemented With
50 mM forskolin (Sigma) for 2 days at the indicated times.
Forskolin Was prepared in DMSO (Sigma) as recommended

25

by Huang et al (1982).

others (Goodman et al, 1979; Ignatius et al, 1985). Because
a differentiated, non-dividing and adherent cell population
Was desired, We ?rst determined Whether continued groWth

Example 5

of cells Was the result of high plating density that may have

RNA Isolation and cDNA Synthesis
Cells Were harvested for RNA isolation from duplicate

30

Wells on the days indicated by scraping cell sheets in PBS
folloWed by centrifugation at 2,000 rpm for 5 min. Cell
pellets Were Washed With PBS, pelleted as above and stored

at loW density Were NGF differentiated in the presence of
35

With DNAse I (Boehringer Mannheim, Indianapolis, Ind.) in
20 mM Tris-HCl (pH 8.4), 2 mMMgCl2, 50 mM KCl, and
10 Units of RNase-free DNase I in a ?nal volume of 20 ml
at room temperature for 15 minutes. DNase I Was inactivated

this determination, cells Were plated at tWo different densi

ties on collagen and non-collagen coated dishes. Cells plated

at —85° C. folloWing removal of PBS. RNA Was isolated

using the Qiagen RNeasy Total RNA Kit as recommended
by the manufacturer. 3 mg of each RNA sample Was treated

exhausted the NGF supplied (Gunning et al, 1981). To make

serum (+serum) Whereas those plated at high density Were
differentiated in the absence of serum (—serum). In collagen
coated Wells containing media supplemented With serum,
the cell density increased more than 30-fold (i.e., from

5.5><103 to 1.9><105 cells/Well) by 17 days post-plating(p.p.)
40

by adding 2 ml EDTA (25 mM, pH 8.0) and heating at 65°

With an additional 12-fold increase (to 2.4><10° cells/Well) in
the folloWing 32 days. The cell density of parallel cultures
groWn on non-coated plates also continued to divide main
taining cell densities of about 50% of those cultured on

C. for 10 min. cDNA Was generated With SuperScript II

collagen-coated dishes. When Nd-PC12 cells Were groWn on

reverse transcriptase (Gibco BRL) and random primers

coated dishes in the absence of serum (—serum) a relatively

(Gibco BRL) as recommended by the supplier. cDNA Was
stored at —20° C. until use.

45

Example 6
RT-PCR

PCR reactions containing 20 mM Tris-HCl (pH 8.4), 50
mM KCl, 1.5mM MgC12, 0.2 mM each dNTP, 0.5 mM of

50

each primer, 2.5 units Taq DNA polymerase (Gibco BRL)
and cDNA derived from 1,500 cells Were prepared on ice.
Samples Were denatured at 94° C. for 3 minutes folloWed by

35 cycles (94° C. for 45 seconds, 550 C. for 30 seconds, 72°
C. for 90 seconds), for HSV target sequences, and 26 cycles,
for the host target. Controls containing 10-fold dilutions of
HSV-1 DNA ranging from 1.25 fg to 12.5 pg (7.5 to 75,000
genome equivalents) or 2-fold dilutions of PC12 cellular
DNA ranging from 0.5 ng to 4.0 ng (155 to 1240 haploid
genome equivalents) Were performed in parallel to assess the
levels of cDNA in each sample. Experimental and control

samples Were performed in duplicate and triplicate, respec
tively. The speci?city of viral speci?c PCR products Were
veri?ed by Southern blot analysis as described by BroWn
(1993). In brief, equivalent amounts of PCR products Were
applied to 2.0% agarose gels and electrophoresed in 0.5><
TBE at 50V for 45—60 min. DNA Was transferred to Magna

55

constant cell number Was maintained for 7 Weeks With a

subsequent loss of about 50% of the cells during the fol
loWing 18 days. Parallel cultures maintained in serum free
conditions did not adhere Well to non-coated dishes. The
addition of serum to minus-serum Nd-PC12 cultures on day
25 pp. resulted in a 70% increase in cell number Within 6

days and an additional 14-fold increase in the folloWing 18
days achieving equivalent cell densities as +serum cultures.
These data demonstrate that a relatively constant number of
Nd-PC12 cells could be maintained as non-dividing cultures
only When cultured in the absence of serum and that cell
groWth arrest is reversible upon the addition of serum to the
media for up to 25 days p.p.

Example 8
Reactivation from Long-term (50 Days) HSV-1 Infected,
60

65

Quiescent PC12 Cultures With Forskolin
To determine Whether Nd-PC12 cells could harbor HSV-1
in a recoverable state for long periods of time folloWing
removal of ACV, Nd-PC12 cultures Were infected With strain
KOS (M) at a MOI of 27+3 on day 15 pp. and maintained
as quiescently infected cultures (QIF-PC12) as described in
FIG. 3. Under these conditions, all cultures Were free of
detectable levels of infectious virus in the supernatants at the

US 6,268,124 B1
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time of ACV WithdraWal. Virus Was detected in only 1 of 35
cultures during the following 8 days, and virus Was not
detected from total cell lysates of our infected control Wells
on day 16 post-ACV WithdraWal. To determine if NGF
WithdraWal Would induce virus production, as described by
Wilcox and Johnson (1987), NGF Was WithdraWn on day 8

ductive infection Was determined folloWing day 1 p.i.,

post-ACV WithdraWal. Virus Was detected by day 8 post
treatment in 100% of forskolin-induced control cultures, 8%
NGF-free cultures, and 5% of infected untreated control
cultures. Except for the detection of virus in 2 of the
remaining 14 infected untreated control Wells on day 17

Whereas levels of LAT remained relatively constant. Tran

script production from the (x0 and UL30 (DNA polymerase
gene) declined the fastest during the ?rst ?ve days p.i. By
day 10 pi. (day of ACV WithdraWal), the level of UL18
(VP23) and a gene expression Was doWn 93—99%, and the
level of UL30 expression fell beloW the level of detection.

FolloWing the WithdraWal of ACV, the expression of these
10

post-ACV WithdraWal, virus Was not detected in infected

control Wells for the remaining 39 days.
To determine Whether these virus negative (non
producing) cultures Were still capable of producing virus, 4
of 12 cultures Were treated With forskolin on day 38, and 4
of 8 Were treated With forskolin on day 49 post-ACV
WithdraWal. Induction With forskolin at these later dates
resulted in the detection of virus in 75 % and 50% of cultures,

Were at the level of detection and beloW. In contrast, LAT

transcripts Were reduced 53% by day 10 pi. but remained
15

levels remained relatively constant throughout the assay

Example 10
Viral Speci?c Product Was not Detected in Uninfected
Control Cultures or in Minus Reverse-transcriptase Controls

untreated control cultures. These data indicate that virus can

be recovered from long-term QIF-PC12 cultures When
induced With forskolin.

Example 9

cells Were established under conditions that minimiZe the
effects of high copy number of viral genomes. This Was
achieved using strain 17 because it reactivates more ef?
ciently in this model than KOS. The infections Were per
formed at an MOI of 0.5. The rate of virus reactivation from
QIF-PC12 cells established under these conditions are pre

sented in a subsequent manuscript (Danaher et al, 1999 J
Neuro Virol). RNAs from duplicate QIF-PC12 cell cultures

25

under similar conditions described in FIG. 2.
30

PC-12 Cells
35

Rat pheochromocytoma (PC-12) cells Were groWn in media

containing 50 ng/mL nerve groWth factor. Thirty-six indi
40

45

50
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(Vero) cells for up to 60 days. Results of the DPA shoWed
that virus Was spontaneously and asynchronously released
from four different culture Wells on days 8, 10, 17 and 32.
Overall, the rate of virus shedding Was 6 of 445 assays

(1.3%). In comparison With ACY treated cultures, 100% of
untreated cultures produced virus continuously until total
cytopathic effect Was achieved (mean 22 days) (p<0.001;
Chi square). These data demonstrate that the majority of
cells do not release virus, and the loW rate of viral shedding
from PC-12 cells is similar to the loW rate of shedding that
occurs in humans (Kameyama et al.,1988). This Work pro
vides preliminary evidence that HSV-1 can be harbored in a

potentially latent state in cell culture, and that these cells

ni?cantly throughout the 31 day period assayed. Expression

may serve as a good model for studies of HSV-1 reactiva

of the host cell gene G3PDH Was constant throughout the

tion.
60

Example 12

from duplicate Southern analysis from duplicate cultures at
each time point of viral RT-PCR products quanti?ed by
densitometry during the 31-day period. The sensitivity in all

HSV-1 Release from PC-12 Cells Induced by Heat Stress
Rat pheochromocytoma PC-12 cells Were groWn under

conditions that result in non-dividing neuronally differenti

cases Was greater than 0.1 target sequences per cell, With a

range of 0.010 to 0.078 represented by VP23 and (X4,
respectively. Consistent With the results shoWn in FIG. 4, a
precipitous decline in viral transcripts associated With pro

vidual cultures in 12-Well plates Were infected With HSV-1
(strain KOS) at a MOI of 20 in the presence of 50 mM

acycloguanosine (ACY). After 10 days, ACY Was removed
(Day 0) and the level of virus replication Was determined by
direct plaque assay (DPA) on monolayers of monkey kidney

drug removal (i.e., 20 days p.i.), as typi?ed by the (x27
product. Transcripts from the UL30 (DNA polymerase
gene), representing the [3 genes, became undetectable by the

time period measured. Table 2 shoWs the values obtained

The lack of an adequate cell culture model for latency of
herpes simplex virus type 1 (HSV-1) contributes to our poor
understanding of HSV-1 reactivation. The objective of this
research Was to establish a latent cell culture model that
supports HSV-1 in a state suitable for reactivation studies.

transcripts from a genes extended to as long as 10 days after

day of ACV WithdraWal (i.e., day 10 pi). Gamma genes, as
represented by UL18 (VP23), Were at, or beloW the level of
detection by day 20 pi In contrast to the precipitous decline
in all classes of viral gene transcripts represented, the stable
LAT transcript persisted, although someWhat reduced com
pared to day 1 pi. levels, for the length of the assay.
From FIG. 4, it is apparent that the products of the
representative viral genes, except for LAT, diminished sig

Example 11
Asynchronous and Spontaneous Release of HSV-1 from

day period and analyZed by RT-PCR in duplicate. The

3 classes of the herpes virus genes (i.e., immediate-early [0t],
early [[3], late
tested folloWing day 1 pi. Detection of

To strengthen the belief that the above analysis Was
undertaken on cells that Were truly quiescent for HSV-1
genomes, parallel 12-Well cultures,that Were determined to
be non-productive, Were treated With forskolin on day 20 pi.
and reactivated With similar kinetics to that of KOS, as

reported in the previous section, With 75% reactivation by 7
day post-forskolin treatment. This experiment Was done

Were collected at the indicated time points throughout the 31

speci?city of the RT-PCR products Were con?rmed by
Southern blot analysis. FIG. 4 shoWs representative results
from one of 4 samples from each time point examining the
viral and host genes (G3PDH gene). Aprecipitous decline in
transcripts occurred from the selected representatives of the

relatively constant thereafter, and never dropped near, or
beloW, the level of detection in the assay. Host G3PDH RNA

period.

respectively, compared With 0% in the remaining infected

Detection of Viral Transcripts During the Establishment and
Maintenance of the Quiescent Phase of QIF-PC12 Cultures
To study viral gene expression during the establishment
and maintenance phases of a quiescent infection, QIF-PC12

genes continued to decline and by day 20 the average cDNA
copies for the ot genes Were beloW the level of detection. By
day 20 and thereafter, the average cDNA copies for UL18

65

ated cells, infected With HSV-1 (17+) at a MOI of <10, and
maintained in acyclovir (ACV) for 10 days as described.
Eight days after ACV removal, cells Were subjected to heat
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(39° C. to 43° C.) for 1 to 3 hrs, or 50 pm forskolin (positive
control). The presence of virus on day 0—25 post-infection
Was determined using supernatants from infected cultures in
a direct plaque assay (dpa).

Rat pheochromocytoma PC12 cells Were groWn under con

ditions that result in non-dividing neuronally differentiated
cells. Cells Were infected With HSV-1 (strains KOS, 17+,
McKrae, and 2903 [a McKrae LAT-de?cient mutant]) at
MOIs 0.5 to 20, and maintained in acycloguanosine (ACV)
for 8 days as described. Virus replication Was detected using
supernatants from infected cultures in a direct plaque assay

Treatment Positive Cultures

Positive Cultures 5d Positive Cultures 7d

(Tx)

post-Tx

post-Tx

post-Tx

39° c.
41° c.
43° c.
Forskolin
DMSO

0/12 (0%)
1/12 (8%)
12/12 (100%)
0/12 (0%)
0/12 (0%)

0/12 (0%)
1/12 (8%)
12/12 (100%)
11/12 (92%)
0/12 (0%)

0/12 (0%)
1/12 (8%)
12/12 (100%)
12/12 (100%)
0/12 (0%)

Negative

0/24 (0%)

0/24 (0%)

0/24 (0%)

control

(dpa) using monkey kidney (Vero) cells. During the Week
folloWing ACV removal, HSV-1 Was detected in 88 and 96%
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of cultures infected With McKrae (MOI=4 and 20,
respectively), 38 and 71% of cultures infected With 17+
(MOI=0.5 and 2.5, respectively), 4 and 12% of cultures
infected With KOS (MOI=1 and 5.6, respectively), and 0%
of cultures infected With 2903 (MOI=2 and 10). These data
indicated that tWo of the strains (KOS, 2903) Were suitable
for reactivation studies. To induce replication in non
productive cells, KOS-and 2903-infected cultures Were sub

Virus Was released more efficiently from cells subjected to

jected to forskolin (50 mm) 20 days post infection.

43° C. and forskolin compared With cells subjected to loWer
temperatures, Whereas no virus Was released from cells

exposed to fresh media +/— DMSO (p<0.001; ANOVA).
Consistent With our previous Work, forskolin induced rep

lication by day 5, hoWever heat stress induced replication in
100% of cultures by day 2. These data shoW that virus
replication can be ef?ciently, predictably and rapidly
induced from a state of nonproductivity by heat shock, and
that this system may serve as a cell culture model for the

study of HSV-1 latency and reactivation.
Example 13
Effect of Hormones on HSV-1 Release from Nonpermissive
PC-12 Cells
This study Was conducted to identify biochemicals that

Strain

MOI

KOS
KOS
2903
2903

1.1
5.6
2
10

Positive Cultures 7d
After MockTreatment

0/11
1/12
0/12
0/12

(0%)
(8%)
(0%)
(0%)

Positive Cultures 7d
After Forskolin
Treatment

7/12
7/9
2/12
2/12

(58%)
(78%)
(17%)
(17%)

Data in the table shoWs that a signi?cantly greater per

centage of cultures produced virus When subjected to for
skolin compared With mock-treated cultures (p<0.01, Chi
square), and a relationship betWeen MOI and inducible
replication in KOS-infected cultures existed. These data

could predictably release virus from this neuronal cell
model. Individual PC-12 cultures groWn, neuronally differ

entiated in 12-Well plates, infected With HSV-1 (strain 17+)

suggest that there is strain speci?city for establishment of a
“latent state” and for inducible-replication in PC12 cells,

at a MOI of <10 and maintained in acyclovir (ACV) for 10

days. Eight days after ACV removal, cells Were subjected to

and that a high viral-to-cell inoculum ratio may provide a

dexamethasone (20, 5, 1, 0.2 MM), epinephrine (100, 50, 10,
1 pM), estrogen (10, 2, 0.5, 0.1 nM), forskolin (50 21M) or

viral advantage for entering latency. Also, the deletion of
LAT sequences may inhibit the virus’ ability to replicate in
neuronally differentiated PC12 cells.

control media. Supernatants from cultures Were removed

daily beginning day 10 post infection and the presence of
virus Was determined by direct plaque assay (dpa) for 18
days post-treatment
An average of <25 plaques per

Example 15
Serotype Speci?city for HSV Replication in PC12 Cells

positive culture Was rated light, an average of 26 to 75
plaques perpositive culture Was rated moderate, and an

replication displayed serotype speci?city in neurally

The aim of this study Was to determine Whether HSV

differentiated, rat pheochromocytoma PC12 cells. Cells

average of >75 plaques per positive culture Was rated heavy.
Results shoWed that forskolin and estrogen caused signi?
cantly more virus replication than the other treatments

(p<0.05, Chi square). Virus replication occurred in 8.0% of
control cultures (days 2—16 pTx), 10.5% of dexamethasone
treated cultures (days 3—7 pTx), 15.3% of epinephrine
treated cultures (days 4—7 pTx), 28.6% of estrogen-treated
cultures (days 5—18 pTx) and 74.3% of forskolin-treated
cultures (days 4—7 pTx). The magnitude of viral release Was
heavy in cultures treated With forskolin and epinephrine,
moderate With estrogen, and light With dexamethasone.
Optimum viral shedding occurred When cells Were treated

With forskolin (50 pm), estrogen (2 nm), epinephrine (10
pm) and dexamethasone (1 pm). These data demonstrate that
estrogen and forskolin trigger virus replication from non
permissive PC12 cells that harbor HSV-1, and that these
agents may be useful for study of events that regulate HSV
reactivation.

Were groWn under conditions that result in non-dividing
neuronally differentiated cells as described, and infected
With HSV-1 or HSV-2 at MOI<1.0 in the presence (HSV-1
strain 17+; HSV-2 strains 333, G) or absence of ACV

(HSV-1 strains 17+, McKrae, KOS, 2903, 2903r). Antiviral
therapy Was continued for 8 days. Virus replication Was
detected using supernatants from infected cultures in a direct

plaque assay (dpa) using monkey kidney (Vero) cells. In the
55

absence of ACV, all HSV-1 strains replicated in PC12 cells,
hoWever HSV-2 (G) did not groW. In the presence of ACV,
a nonproductive state Was established. In an attempt to

induce replication in non-productive cells, cultures Were
subjected to forskolin (50 mM) or heat stress (43° C., 3 hrs)

19 days and 26 days post infection [pi], respectively. HSV-1
(17+) Was shed from 12/12 cultures 4 days after forskolin
treatment and 32/33 cultures 2 days after heat stress com

pared With 2/22 control cultures (p<0.01, Chi square).
HSV-2 (333) Was minimally shed from 4/46 cultures 2 days

Example 14
Strain Speci?city for HSV-1 Replication in PC12 Cells
The aim of this study Was to determine Whether our cell

culture model for HSV-1 latency displayed strain speci?city.

after heat stress, 1/24 cultures after forskolin treatment and
0/23 control cultures. HSV-2 (G) Was shed from 1/24
cultures 2 days after heat stress, 0/ 12 cultures after forskolin
treatment and 0/12 control cultures. These data suggest that

US 6,268,124 B1
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there is serotype speci?city for HSV replication, and
inducible-replication, in PC12 cells, and that ACV affects

introducing a reactivator to a PC12 cell of claim 1,
Wherein the neurotropic virus is an attenuated neuro

this susceptibility.

tropic virus; and

We claim:
1. APC12 cell quiescently infected With a human herpes

determining the relative magnitude of reactivation.
11. A method of establishing quiescently-infected PC12

simpleX 1 virus.

cells, comprising:

2. A method of reactivating a quiescent virus from at least

introducing a human herpes simpleX 1 virus to neurally

one quiescently-infected PC12 cell, comprising: introducing

differentiated and viable PC12 cells in a serum-free

a reactivator to a cell of claim 1.

medium, said differentiated PC12 cells being in a

3. A method for determining the ability of a test reagent

container; and

to suppress virus reactivation from a quiescently-infected

incubating said container With an antiviral reagent for a

PC12 cell of claim 1, comprising:

time necessary to accomplish quiescence of viral activ

introducing a test reagent to said PC12 cell; and
introducing to said PC12 cell a reactivator; and

ity; and
removing said antiviral agent from said container.
12. The method of claim 11, Wherein the antiviral reagent

determining if reactivation has been suppressed.

is acyclovir.

4. A method for determining the ability of a test reagent

13. The method of claim 12, Wherein said container is

to induce virus reactivation from a PC12 cell of claim 1,

comprising:
introducing a test reagent to said PC12 cell; and

determining if reactivation has been induced.
5. Amethod for eliciting phenotypic change in a PC12 cell
of claim 1,
introducing a reactivator to said PC12 cell, and
eliciting a phenotypic change in said PC12 cell.
6. The method of claim 5 Wherein said phenotypic change
is selected from the group consisting of synthesis of myelin,

incubated With acyclovir for approximately 5 to 12 days.
20

medium alloWs for constant cell density and imparts neural
characteristics to said cells.
25

introducing a non-neurotropic virus to differentiated and
viable PC12 cells in a serum-free medium, said differ
entiated PC12 cells being in a container; and
incubating said container With an antiviral reagent for a
time necessary to accomplish quiescence of viral activ

7. A method for determining the susceptibility of a person
infected With a quiescent virus to reactivation by a reagent,

comprising:
introducing a reactivator to a PC12 cell of claim 1,
Wherein the neurotropic virus is a strain isolated from

ity; and
removing said antiviral agent from said container; and
determining said non-neurotropic virus’ ability to become

a person infected With said neurotropic virus; and

determining the relative magnitude of phenotypic or

quiescent and/or reactivatable.

genomic reactivation.

17. A method to determine a reagent’s ability to inhibit

8. A method to identify nucleic acid molecules and/or

establishment of a quiescent viral infection, comprising:

proteins involved in virus reactivation, comprising:

introducing a virus to differentiated and viable PC12 cells

reactivating a PC12 cell of claim 1 With a reactivator; and

in a serum-free, test reagent-containing medium, said
differentiated PC12 cells being in a container; and
incubating said container With an antiviral reagent for a
time necessary to accomplish quiescence of viral activ
ity in the absence of said test reagent; and

identifying nucleic acid molecules and/or proteins Which
are uniquely expressed during reactivation.
9. A method to identify the origins of DNA replication
important to virus reactivation, comprising:

identifying the origins of replication Which are uniquely
associated With reactivation.
10. Amethod to screen an altered virus’ relative ability to

be reactivated, comprising:

16. Amethod to determine the ability of a non-neurotropic
virus to become quiescent and/or reactivatable in a PC12

cell line, comprising:

synthesis of neurotransmitter, cell death, and viral shedding.

reactivating a PC12 cell of claim 1 With a reactivator; and

14. The method of claim 13, Wherein said container is
incubated at a temperature less than 40 degrees Celsius.
15. The method of claim 12, Wherein said serum free

45

removing said antiviral agent from said container; and
determining said test reagent’s ability to inhibit quies
cence.

